Incyte   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Palo Alto CA United States (1991)

Organization Overview

First Clinical Trial
2005
NCT00820560
First Marketed Drug
2011
ruxolitinib (jakafi)
First NDA Approval
2011
ruxolitinib (jakafi)
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Incyte Biosciences International Sàrl | Incyte Biosciences Japan GK | Incyte Biosciences UK | Incyte Biosciences UK Ltd | Incyte Corp. | INCYTE CORP | Incyte Corporation | Incyte Pharmaceuticals